|
1
|
Sauer R, Liersch T, Merkel S, Fietkau R,
Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann
H, et al: Preoperative versus postoperative chemoradiotherapy for
locally advanced rectal cancer: Results of the German
CAO/ARO/AIO-94 randomized phase III trial after a median follow-up
of 11 years. J Clin Oncol. 30:1926–1933. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sauer R, Becker H, Hohenberger W, Rödel C,
Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF,
et al: Preoperative versus postoperative chemoradiotherapy for
rectal cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rödel C, Hofheinz R and Fokas E: Rectal
cancer: Neoadjuvant chemoradiotherapy. Best Pract Res Clin
Gastroenterol. 30:629–639. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rödel C, Graeven U, Fietkau R, Hohenberger
W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA,
Lang-Welzenbach M, et al: Oxaliplatin added to fluorouracil-based
preoperative chemoradiotherapy and postoperative chemotherapy of
locally advanced rectal cancer (the German CAO/ARO/AIO-04 study):
Final results of the multicentre, open-label, randomised, phase 3
trial. Lancet Oncol. 16:979–989. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aschele C, Cionini L, Lonardi S, Pinto C,
Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti
P, et al: Primary tumor response to preoperative chemoradiation
with or without oxaliplatin in locally advanced rectal cancer:
Pathologic results of the STAR-01 randomized phase III trial. J
Clin Oncol. 29:2773–2780. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gérard JP, Azria D, Gourgou-Bourgade S,
Martel-Lafay I, Hennequin C, Etienne PL, Vendrely V, François E, de
La Roche G, Bouché O, et al: Clinical outcome of the ACCORD 12/0405
PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol.
30:4558–4565. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
O'Connell MJ, Colangelo LH, Beart RW,
Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC,
Ryan DP, et al: Capecitabine and oxaliplatin in the preoperative
multimodality treatment of rectal cancer: Surgical end points from
National surgical adjuvant breast and bowel project trial R-04. J
Clin Oncol. 32:1927–1934. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iles S, Gollins S, Susnerwala S, Haylock
B, Myint S, Biswas A, Swindell R and Levine E:
Irinotecan+5-fluorouracil with concomitant pre-operative
radiotherapy in locally advanced non-resectable rectal cancer: A
phase I/II study. Br J Cancer. 98:1210–1216. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mehta VK, Cho C, Ford JM, Jambalos C, Poen
J, Koong A, Lin A, Bastidas JA, Young H, Dunphy EP and Fisher G:
Phase II trial of preoperative 3D conformal radiotherapy,
protracted venous infusion 5-fluorouracil, and weekly CPT-11,
followed by surgery for ultrasound-staged T3 rectal cancer. Int J
Radiat Oncol Biol Phys. 55:132–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mohiuddin M, Winter K, Mitchell E, Hanna
N, Yuen A, Nichols C, Shane R, Hayostek C and Willett C;: Radiation
Therapy Oncology Group Trial 0012: Randomized phase II study of
neoadjuvant combined-modality chemoradiation for distal rectal
cancer: Radiation therapy oncology group trial 0012. J Clin Oncol.
24:650–655. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Navarro M, Dotor E, Rivera F,
Sánchez-Rovira P, Vega-Villegas ME, Cervantes A, García JL, Gallén
M and Aranda E: A Phase II study of preoperative radiotherapy and
concomitant weekly irinotecan in combination with protracted venous
infusion 5-fluorouracil, for resectable locally advanced rectal
cancer. Int J Radiat Oncol Biol Phys. 66:201–205. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Willeke F, Horisberger K,
Kraus-Tiefenbacher U, Wenz F, Leitner A, Hochhaus A, Grobholz R,
Willer A, Kähler G, Post S and Hofheinz RD: A phase II study of
capecitabine and irinotecan in combination with concurrent pelvic
radiotherapy (CapIri-RT) as neoadjuvant treatment of locally
advanced rectal cancer. Br J Cancer. 96:912–917. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gollins S, Sun Myint A, Haylock B, Wise M,
Saunders M, Neupane R, Essapen S, Samuel L, Dougal M, Lloyd A, et
al: Preoperative chemoradiotherapy using concurrent capecitabine
and irinotecan in magnetic resonance imaging-defined locally
advanced rectal cancer: Impact on long-term clinical outcomes. J
Clin Oncol. 29:1042–1049. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shirasaka T, Shimamato Y, Ohshimo H,
Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a
novel form of an oral 5-fluorouracil derivative (S-1) directed to
the potentiation of the tumor selective cytotoxicity of
5-fluorouracil by two biochemical modulators. Anticancer Drugs.
7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Malet-Martino M and Martino R: Clinical
studies of three oral prodrugs of 5-fluorouracil (capecitabine,
UFT, S-1): A review. Oncologist. 7:288–323. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shirao K, Ohtsu A, Takada H, Mitachi Y,
Hirakawa K, Horikoshi N, Okamura T, Hirata K, Saitoh S, Isomoto H
and Satoh A: Phase II study of oral S-1 for treatment of metastatic
colorectal carcinoma. Cancer. 100:2355–2361. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sadahiro S, Suzuki T, Tanaka A, Okada K,
Kamijo A, Murayama C, Akiba T and Nakayama Y: Phase I/II study of
preoperative concurrent chemoradiotherapy with S-1 for locally
advanced, resectable rectal adenocarcinoma. Oncology. 81:306–311.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sato T, Ozawa H, Hatate K, Onosato W,
Naito M, Nakamura T, Ihara A, Koizumi W, Hayakawa K, Okayasu I, et
al: A Phase II trial of neoadjuvant preoperative chemoradiotherapy
with S-1 plus irinotecan and radiation in patients with locally
advanced rectal cancer: Clinical feasibility and response rate. Int
J Radiat Oncol Biol Phys. 79:677–683. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Matsusaka S, Ishihara S, Kondo K, Horie H,
Uehara K, Oguchi M, Murofushi K, Ueno M, Mizunuma N, Shimbo T, et
al: A multicenter phase II study of preoperative chemoradiotherapy
with S-1 plus oxaliplatin for locally advanced rectal cancer
(SHOGUN trial). Radiother Oncol. 116:209–213. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marques RP, Duarte GS, Sterrantino C, Pais
HL, Quintela A, Martins AP and Costa J: Triplet (FOLFOXIRI) versus
doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line
treatment of metastatic colorectal cancer: A systematic review and
meta-analysis. Crit Rev Oncol Hematol. 118:54–62. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hardiman KM, Ulintz PJ, Kuick RD, Hovelson
DH, Gates CM, Bhasi A, Rodrigues Grant A, Liu J, Cani AK, Greenson
JK, et al: Intra-tumor genetic heterogeneity in rectal cancer. Lab
Invest. 96:4–15. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Panczyk M: Pharmacogenetics research on
chemotherapy resistance in colorectal cancer over the last 20
years. World J Gastroenterol. 20:9775–9827. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Greenhalgh TA, Dearman C and Sharma RA:
Combination of novel agents with radiotherapy to treat rectal
cancer. Clin Oncol (R Coll Radiol). 28:116–139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lawrence TS, Blackstock AW and McGinn C:
The mechanism of action of radiosensitization of conventional
chemotherapeutic agents. Semin Radiat Oncol. 13:13–21. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hill EJ, Nicolay NH, Middleton MR and
Sharma RA: Oxaliplatin as a radiosensitiser for upper and lower
gastrointestinal tract malignancies: What have we learned from a
decade of translational research? Crit Rev Oncol Hematol.
83:353–387. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu AX and Willett CG: Chemotherapeutic
and biologic agents as radiosensitizers in rectal cancer. Semin
Radiat Oncol. 13:454–468. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Leal F, Ferreira FP and Sasse AD:
FOLFOXIRI regimen for metastatic colorectal cancer: A systematic
review and meta-analysis. Clin Colorectal Cancer. 16:405–409.e2.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jung M, Shin SJ, Koom WS, Jung I, Keum KC,
Hur H, Min BS, Baik SH, Kim NK, Kim H, et al: A randomized phase 2
study of neoadjuvant chemoradiaton therapy with
5-fluorouracil/leucovorin or irinotecan/S-1 in patients with
locally advanced rectal cancer. Int J Radiat Oncol Biol Phys.
93:1015–1022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hong YS, Kim DY, Lim SB, Choi HS, Jeong
SY, Jeong JY, Sohn DK, Kim DH, Chang HJ, Park JG and Jung KH:
Preoperative chemoradiation with irinotecan and capecitabine in
patients with locally advanced resectable rectal cancer: Long-term
results of a Phase II study. Int J Radiat Oncol Biol Phys.
79:1171–1178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sato T, Hayakawa K, Tomita N, Noda M,
Kamikonya N, Watanabe T, Kato D, Sakai Y, Hiraoka M, Shimada M, et
al: A multicenter phase I study of preoperative chemoradiotherapy
with S-1 and irinotecan for locally advanced lower rectal cancer
(SAMRAI-1). Radiother Oncol. 120:222–227. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ishihara S, Matsusaka S, Kondo K, Horie H,
Uehara K, Oguchi M, Murofushi K, Ueno M, Mizunuma N, Shinbo T, et
al: A phase I dose escalation study of oxaliplatin plus oral S-1
and pelvic radiation in patients with locally advanced rectal
cancer (SHOGUN trial). Radiat Oncol. 10:242015. View Article : Google Scholar : PubMed/NCBI
|
